Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK) - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Guidelines for the Management of ATTR-CM in Germany: Consensus from the German Society of Amyloid Diseases and the German Cardiac Society

  • By

  • Fabian aus dem Siepen

  • Teresa Trenkwalder

  • Birgit Aßmus

  • Ingrid Kindermann

  • Daniel Lavall

  • Sebastian Spethmann

  • Lars Michel

  • Timon Hansen

  • Sebastian Kruck

  • Christoph Rischpler

  • Fabian Knebel

  • Stéphanie K. Schwarting

  • Udo Bavendiek

  • Maria Papathanasiou

  • Ute Hegenbart

  • Ali Yilmaz

  • Katrin Hahn

  • Alexander Carpinteiro

  • Roman Pfister

  • Caroline Morbach

  • September 22, 2026

Share

Objective:

To present recommendations for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on current evidence and expert consensus in Germany.

Approach:
  • Expert Consensus Development: The expert panel evaluated clinical outcomes, drug tolerability, and individualized treatment considerations, referencing published manuscripts and peer-reviewed abstracts.
Key Findings:
  • Tafamidis and acoramidis are approved TTR stabilizers, while vutrisiran is a TTR gene silencer for ATTR-CM treatment.
  • Tafamidis has shown significant efficacy in reducing all-cause mortality and cardiovascular-related hospitalizations in the ATTR-ACT trial.
  • Tafamidis demonstrated sustained tolerability with a safety profile similar to placebo, with mild to moderate adverse events being most common.
Interpretation:

The findings underscore the importance of TTR stabilization in managing ATTR-CM, highlighting the role of tafamidis and acoramidis in improving patient outcomes. The evidence supports the use of these therapies to enhance quality of life and reduce hospitalizations, although the variability in study designs necessitates careful consideration when applying these findings to clinical practice.

Limitations:
  • Lack of head-to-head trials for direct comparison of treatment agents.
  • Variability in study design and patient populations complicates the interpretation of results.
Conclusion:

The consensus provides a framework for individualized treatment decisions in ATTR-CM management in Germany, emphasizing the need for ongoing research to address existing limitations and improve therapeutic strategies.

Original Source(s)

Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK)

  • by Fabian aus dem Siepen, Teresa Trenkwalder, Birgit Aßmus, Ingrid Kindermann, Daniel Lavall, Sebastian Spethmann, Lars Michel, Timon Hansen, Sebastian Kruck, Christoph Rischpler, Fabian Knebel, Stéphanie K. Schwarting, Udo Bavendiek, Maria Papathanasiou, Ute Hegenbart, Ali Yilmaz, Katrin Hahn, Alexander Carpinteiro, Roman Pfister, Caroline Morbach

  • September 22, 2026

Related Content

Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy

Can GDMT Be Safely Stopped After AF Ablation?

Three of 23 patients experienced heart failure deterioration following medication withdrawal, while adverse drug events occurred only among patients who continued therapy.

Mobile Integrated Health and Post–Hospital Discharge Heart Failure Care